“We work systematically to strengthen our core business by delivering growth through the introduction of new products in existing markets and expanding products to new geographies. We have started and will continue the tedious process to increase company value by owning new products and brands. As a third step, we have been and will actively continue to source and evaluate M&A opportunities to deliver sustainable growth with the objective of building Navamedic to a leading Nordic pharmaceutical company with a footprint in North Europe and other selected countries,” says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
Stock exchange news
Handelsbanken Liquidity Provider in Navamedic
The Liquidity Provider scheme is based on standard agreements developed by the Norwegian Securities Dealers Association and reviewed by Oslo Read more
Navamedic sells chitin to Lytone Enterprise Inc. in Taiwan
The LOI between Navamedic's 100% owned subsidiary ChitiNor AS and Lytone Enterprise, Inc. in Taiwan covers the chitin production for Read more
Treating the side-effects of the pandemic
Musculoskeletal pain is often a result of muscle tension and overexertion, psychological stress or working postures, often in combination with Read more
Meet us at exhibitions and fairs
Unfortunately, due to Covid-19. Exhibitions are postponed or cancelled until further notice.